Aptamer Group (LSE:APTA) FCF Margin % : -603.02% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aptamer Group's Free Cash Flow for the six months ended in Dec. 2023 was £-1.80 Mil. Aptamer Group's Revenue for the six months ended in Dec. 2023 was £0.30 Mil. Therefore, Aptamer Group's FCF Margin % for the quarter that ended in Dec. 2023 was -603.02%.

As of today, Aptamer Group's current FCF Yield % is -86.49%.

The historical rank and industry rank for Aptamer Group's FCF Margin % or its related term are showing as below:

LSE:APTA' s FCF Margin % Range Over the Past 10 Years
Min: -347.72 Med: -79.49 Max: -28.54
Current: -312.46

During the past 4 years, the highest FCF Margin % of Aptamer Group was -28.54%. The lowest was -347.72%. And the median was -79.49%.

LSE:APTA's FCF Margin % is ranked worse than
60.13% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs LSE:APTA: -312.46

Aptamer Group FCF Margin % Historical Data

The historical data trend for Aptamer Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group FCF Margin % Chart

Aptamer Group Annual Data

Trend

Mar19

Mar20

Jun22

Jun23

FCF Margin %

-89.77

-28.54

-69.20

-347.72

Aptamer Group Semi-Annual Data
	Mar19	Mar20	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-3.20	-103.23	-458.62	-194.98	-603.02

Competitive Comparison of Aptamer Group's FCF Margin %

For the Biotechnology subindustry, Aptamer Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptamer Group's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptamer Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aptamer Group's FCF Margin % falls into.

Aptamer Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aptamer Group's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-6.092	/	1.752
	=	-347.72 %

Aptamer Group's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.797	/	0.298
	=	-603.02 %

Aptamer Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aptamer Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptamer Group (LSE:APTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

P0J:Germany

Address

Innovation Way, Windmill House, York, GBR, YO10 5BR

Website

https://www.aptamergroup.com

Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines